Related Experiment Video
Updated: Apr 11, 2026

Author Spotlight: Understanding Chronic Lung Diseases Using 3D Printed Phototunable Hydrogels
Published on: June 30, 2023
Inhibition of (interstitial) P2Y6 receptors attenuates fibrosis progression
Lena Marie Süß1, Anna Petzendorfer1, Minh Linh Tran1
1University of Regensburg.
Abstract:
Chronic kidney disease (CKD) affects over 850 million people worldwide and is characterized by progressive renal fibrosis driven by activated interstitial fibroblasts. Signaling by extracellular nucleotides and P2 receptors plays an important role in renal pathophysiology, yet its contribution to fibroblast activation and fibrosis remains poorly understood. Here, we investigated the expression and function of Gq/11-coupled P2Y receptors in renal interstitial fibroblasts and their involvement in experimental kidney fibrosis. Using highly selective RNA in situ hybridization, we detected P2Y1 (P2ry1) and P2Y6 (P2ry6) receptor expression in interstitial fibroblasts. Notably, P2Y6 expression was markedly upregulated in several experimental mouse models of renal fibrosis. Functional assays in primary cultured renal fibroblasts confirmed Gq/11-coupled P2Y receptor activity, as evidenced by transient intracellular Ca2 + elevations upon nucleotide stimulation. Primary cultured renal fibroblasts exhibited enhanced migration in response to extracellular uridine diphosphate (UDP). To assess the contribution of interstitial P2Y6 receptors to fibrosis progression, we employed an adenine-induced nephropathy model with or without the selective P2Y6 antagonist MRS2578. Pharmacological inhibition of P2Y6 significantly reduced the mRNA expression of the myofibroblast marker α-smooth muscle actin and collagen I. Collectively, these findings suggest that upregulated P2Y6 receptor signaling promotes the transition of resident interstitial cells into myofibroblasts during renal fibrosis, likely by modulating fibroblast migration. Inhibition of P2Y6 signaling could represent a new strategy for reducing excessive renal fibrosis.
Insights
Extracellular nucleotide signaling via P2Y6 receptors promotes kidney fibrosis by activating interstitial fibroblasts. Inhibiting P2Y6 receptors may offer a novel therapeutic strategy for reducing renal fibrosis in chronic kidney disease.
Area of Science:
- Nephrology
- Molecular Biology
- Cell Biology
Background:
- Chronic kidney disease (CKD) affects over 850 million people globally, characterized by progressive renal fibrosis.
- Activated interstitial fibroblasts are key drivers of renal fibrosis.
- The role of extracellular nucleotide and P2 receptor signaling in fibroblast activation and fibrosis is not well understood.
Purpose of the Study:
- Investigate the expression and function of Gq/11-coupled P2Y receptors in renal interstitial fibroblasts.
- Determine the involvement of these receptors in experimental kidney fibrosis.
- Explore P2Y6 receptor signaling as a potential therapeutic target for renal fibrosis.
Main Methods:
- RNA in situ hybridization to detect P2Y1 and P2Y6 receptor expression in fibroblasts.
- Functional assays measuring intracellular calcium (Ca2+) elevation and fibroblast migration.
- Adenine-induced nephropathy mouse model treated with a selective P2Y6 antagonist (MRS2578).
Main Results:
- P2Y1 and P2Y6 receptors were detected in interstitial fibroblasts, with P2Y6 significantly upregulated in fibrotic kidneys.
- Nucleotide stimulation induced intracellular Ca2+ elevation and enhanced fibroblast migration.
- P2Y6 receptor inhibition reduced myofibroblast markers (α-smooth muscle actin) and collagen I expression in vivo.
Conclusions:
- Upregulated P2Y6 receptor signaling in renal interstitial fibroblasts contributes to myofibroblast activation and fibrosis progression.
- P2Y6 receptor signaling modulates fibroblast migration, promoting fibrotic transitions.
- Inhibiting P2Y6 signaling presents a potential new therapeutic approach for managing renal fibrosis.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Intracellular Signaling Affects Focal Adhesions
Some...
Clot Retraction and Fibrinolysis
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...